Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human osteopontin (rhOPN) is a recombinant form of the human osteopontin protein, a multifunctional matricellular glycophosphoprotein encoded by the SPP1 gene. It serves as a ligand for several integrin receptors (such as alpha-v beta-3, alpha-v beta-1, and alpha-v beta-5) and the CD44 receptor, mediating cell-matrix interactions and activating signaling pathways involved in inflammation, immune response, and tissue remodeling. In oncology research, rhOPN has been investigated for its role in colitis-associated carcinoma (CAC), where it appears to modulate mitochondrial respiratory chain activity and promote tumor cell proliferation. While primarily utilized as a research-use-only (RUO) reagent for in vitro and in vivo studies, its signaling pathways are significant targets in inflammatory and neoplastic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human osteopontin.